Your shopping cart is currently empty

TLK117 is an inhibitor of GSTs that reduces the severity of pulmonary fibrosis and can be used to study idiopathic pulmonary fibrosis.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $149 | 7-10 days | 7-10 days |
| Description | TLK117 is an inhibitor of GSTs that reduces the severity of pulmonary fibrosis and can be used to study idiopathic pulmonary fibrosis. |
| Targets&IC50 | glutathione S-transferase P:0.4 μM (Ki), aldolase I:0.56 μM (Ki) |
| In vitro | TLK117 is a potent and specific glutathione S-transferase P (GSTP) inhibitor with a higher binding affinity to the target than glutathione (GSH) and more than 50-fold selectivity for GSTP compared to GSTM and GSTA classes, with a constant of inhibition (Ki) of 0.4 μM.[1] TLK117 was developed as an inhibitor of the GST P1-1 isoenzyme to address the critical role of GST P1-1 in drug resistance in tumor cells. To enhance the cellular uptake efficiency of TLK117, the compound is delivered as a diethyl ester (TER 117 DEE, also known as TER 199).TLK117 competitively inhibits GST P1-1 and aldolase I. The inhibition constant (Ki) of TLK117 on aldolase I is 0.56 μM.[2] |
| In vivo | In cases where fibrosis has already formed, TLK117 attenuates pathological changes by inhibiting GSTP to attenuate tissue remodeling induced by bleomycin and adenoviral TGFβ (AdTGFβ), and decreasing the levels of α-SMA, cysteine asparaginase activity, FAS S-glutathionylation, and total protein S-glutathionylation. Within 4 hours after administration of 50 mg/kg TLK117, GSTP activity was substantially reduced and maintained at approximately 60% inhibition for at least 24 hours. [2] |
| Synonyms | TLK-117, TER-117, TER117 |
| Molecular Weight | 473.54 |
| Formula | C23H27N3O6S |
| Cas No. | 152684-53-2 |
| Smiles | [C@H](NC([C@@H](NC(CC[C@@H](C(O)=O)N)=O)CSCC1=CC=CC=C1)=O)(C(O)=O)C2=CC=CC=C2 |
| Relative Density. | 1.346 g/cm3 (Predicted) |
| Sequence | H-gGlu-Cys(Bn)-D-Phg-OH |
| Sequence Short | XXX |
| Storage | keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 150 mg/mL (316.76 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (8.45 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.